stronger than tirzepatide A 72-week trial compared the two leading GLP-1 medications in adults with obesity (no diabetes). The results: ✓ Tirzepatide: 20.2% weight loss ✓ Semaglutide: 13.7% weight loss But weight loss isn't the Why You Might Tolerate One
Description
Tirzepatide is available in pre-filled, single-dose pens of 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg and 15 mg
:max_bytes(150000):strip_icc()/Health-GettyImages-2153927815-0bf99cd73e2c46908d7fc0973739f6d0.jpg)
Partnering with Ivologist guarantees clarity at every step, from the initial consultation to creating a treatment plan

There has been a large phase 3 clinical trial programme, SURMOUNT, undertaken in people who do not have diabetes
No fumbling with oversized syringes
Tolerability Adverse effects are similar to those of other GLP-1 receptor agonists
